Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2014 (2014), Article ID 560620, 8 pages
http://dx.doi.org/10.1155/2014/560620
Research Article

Fructose Induced Endotoxemia in Pediatric Nonalcoholic Fatty Liver Disease

1Department of Pediatrics, School of Medicine, Emory University, 2015 Uppergate Drive NE, Atlanta, GA 30322, USA
2Medical University of South Carolina, Charleston, SC 29425, USA
3Department of Statistics, Emory University, Atlanta, GA 30322, USA
4School of Medicine, University of Louisville, Louisville, KY 40202, USA
5Robley Rex Louisville VAMC, Louisville, KY 40206, USA
6Children’s Healthcare of Atlanta, Atlanta, GA 30329, USA

Received 8 May 2014; Revised 9 September 2014; Accepted 10 September 2014; Published 28 September 2014

Academic Editor: Matthias Bahr

Copyright © 2014 Ran Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Welsh, S. Karpen, and M. B. Vos, “Increasing prevalence of nonalcoholic fatty liver disease among united states adolescents, 1988–1994 to 2007–2010,” Journal of Pediatrics, vol. 162, no. 3, pp. 496.e1–500.e1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. L. Harte, N. F. Da Silva, S. J. Creely et al., “Elevated endotoxin levels in non-alcoholic fatty liver disease,” Journal of Inflammation, vol. 7, article 15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Thuy, R. Ladurner, V. Volynets et al., “Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake,” Journal of Nutrition, vol. 138, no. 8, pp. 1452–1455, 2008. View at Google Scholar · View at Scopus
  4. F. J. Verdam, S. S. Rensen, A. Driessen, J. W. Greve, and W. A. Buurman, “Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis,” Journal of Clinical Gastroenterology, vol. 45, no. 2, pp. 149–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Alisi, M. Manco, R. Devito, F. Piemonte, and V. Nobili, “Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 50, no. 6, pp. 645–649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. I. Lassenius, K. H. Pietiläinen, K. Kaartinen et al., “Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation,” Diabetes Care, vol. 34, no. 8, pp. 1809–1815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. F. Teixeira, M. C. Collado, C. L. L. F. Ferreira, J. Bressan, and M. D. C. G. Peluzio, “Potential mechanisms for the emerging link between obesity and increased intestinal permeability,” Nutrition Research, vol. 32, no. 9, pp. 637–647, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S. C. Bischoff, and I. Bergheim, “Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice,” Hepatology, vol. 50, no. 4, pp. 1094–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Bergheim, S. Weber, M. Vos et al., “Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin,” Journal of Hepatology, vol. 48, no. 6, pp. 983–992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. B. Vos, J. E. Kimmons, C. Gillespie, J. Welsh, and H. M. Blank, “Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey,” MedGenMed Medscape General Medicine, vol. 10, no. 7, article 160, 2008. View at Google Scholar · View at Scopus
  11. R. Jin, N.-A. Le, S. Liu et al., “Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. E1088–E1098, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Jin, J. A. Welsh, N. A. Le et al., “Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD,” Nutrients, vol. 6, pp. 3187–3201, 2014. View at Google Scholar
  13. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. B. Vos and J. E. Lavine, “Dietary fructose in nonalcoholic fatty liver disease,” Hepatology, vol. 57, no. 6, pp. 2525–2531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. C. M. Leevy, “Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature,” Medicine, vol. 41, pp. 249–276, 1962. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Pineda, P. Sharma, Q. Xu, X. Hu, M. Vos, and D. R. Martin, “Measurement of hepatic lipid: High-speed T2-corrected multiecho acquisition at 1H MR spectroscopy—a rapid and accurate technique,” Radiology, vol. 252, no. 2, pp. 568–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A.-X. L. Holterman, G. Guzman, G. Fantuzzi et al., “Nonalcoholic fatty liver disease in severely obese adolescent and adult patients,” Obesity, vol. 21, no. 3, pp. 591–597, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. T. H. Frazier, J. K. DiBaise, and C. J. McClain, “Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury,” Journal of Parenteral and Enteral Nutrition, vol. 35, no. 5, supplement, pp. 14S–20S, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Brun, I. Castagliuolo, V. Di Leo et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 292, no. 2, pp. G518–G525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Creely, P. G. McTernan, C. M. Kusminski et al., “Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 292, no. 3, pp. E740–E747, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. N. van der Crabben, R. M. E. Blümer, M. E. Stegenga et al., “Early endotoxemia increases peripheral and hepatic insulin sensitivity in healthy humans,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 2, pp. 463–468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. O. Agwunobi, C. Reid, P. Maycock, R. A. Little, and G. L. Carlson, “Insulin resistance mid substrate utilization in human endotoxemia,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3770–3778, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. N. N. Mehta, F. C. McGillicuddy, P. D. Anderson et al., “Experimental endotoxemia induces adipose inflammation and insulin resistance in humans,” Diabetes, vol. 59, no. 1, pp. 172–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ueki, T. Kondo, and C. R. Kahn, “Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms,” Molecular and Cellular Biology, vol. 24, no. 12, pp. 5434–5446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Shi, L. Dong, X. Dang et al., “Effect of chlorogenic acid on LPS-induced proinflammatory signaling in hepatic stellate cells,” Inflammation Research, vol. 62, no. 6, pp. 581–587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” The Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Zuany-Amorim, J. Hastewell, and C. Walker, “Toll-like receptors as potential therapeutic targets for multiple diseases,” Nature Reviews Drug Discovery, vol. 1, no. 10, pp. 797–807, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Miele, V. Valenza, G. La Torre et al., “Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease,” Hepatology, vol. 49, no. 6, pp. 1877–1887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Wagnerberger, A. Spruss, G. Kanuri et al., “Toll-like receptors 1–9 are elevated in livers with fructose-induced hepatic steatosis,” British Journal of Nutrition, vol. 107, no. 12, pp. 1727–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Spruss, G. Kanuri, C. Stahl, S. C. Bischoff, and I. Bergheim, “Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function,” Laboratory Investigation, vol. 92, no. 7, pp. 1020–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Volynets, M. A. Küper, S. Strahl et al., “Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD),” Digestive Diseases and Sciences, vol. 57, no. 7, pp. 1932–1941, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Giorgio, L. Miele, L. Principessa et al., “Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity,” Digestive and Liver Disease, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Baffy, “Kupffer cells in non-alcoholic fatty liver disease: the emerging view,” Journal of Hepatology, vol. 51, no. 1, pp. 212–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Volynets, J. Machann, M. A. Küper et al., “A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study,” European Journal of Nutrition, vol. 52, no. 2, pp. 527–535, 2013. View at Publisher · View at Google Scholar · View at Scopus